Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gastroenterology

• Publication date

  2016-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2016.06.032PMID 27374366PMCID PMC6042851
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bench to bedside: NK cells and control of metastasis.

  2017cited by this paper
• Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.

  2016cited by this paper
• Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

  2015cited by this paper
• Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

  2015cited by this paper
• Effect of Surgery on Pancreatic Tumor-Dependent Lymphocyte Asset

  2015cited by this paper
• Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy

  2015cited by this paper
• Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

  2015cited by this paper
• Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.

  2015cited by this paper
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

  2014cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Therapeutic advances in pancreatic cancer.

  2013cited by this paper
• Low‐dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

  2013cited by this paper
• What we have learned about pancreatic cancer from mouse models.

  2012cited by this paper
• Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.

  2009cited by this paper
• Genetics and biology of pancreatic ductal adenocarcinoma.

  2006cited by this paper
• Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

  2005cited by this paper
• Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

  1998cited by this paper

• Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer

  2026cites this paper
• Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy

  2025cites this paper
• Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer

  2025cites this paper
• A case of Inoperable Chemotherapy-resistant Pleural Mesothelioma Treated with Subcutaneous Administration of Inactivated Sendai Virus Particles (HVJ-E) and Concurrent Chemotherapy for the First Time after the HVJ-E P-I Trial

  2025cites this paper
• The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer

  2023cites this paper
• Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function.

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment

  2021cites this paper
• Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• The Potential for Circulating Tumor Cells in Pancreatic Cancer Management

  2017cites this paper